TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25277416

Group type: EXPERIMENTAL
Intervention: Self-efficacy based exercise intervention (individualised program of calf muscle exercises and walking, 12 weeks duration, includes up to six telephone delivered behavioural coaching and goal setting sessions, supported by written materials, a pedometer, and two follow-up booster calls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care as recommended by evidence based guidelines, supported by a generic information sheet encouraging lower limb exercises, a pedometer for self-management, and phone calls at the same time points as the intervention group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy based exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21874629

Group type: EXPERIMENTAL
Intervention: Coagulation with the new semiautomated VITE-function of VISULAS 532 s (pulse duration 20 ms, power 286 mW)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional single-spot coagulation (pulse duration 100-150 ms, power 157 mW)
Number of subjects: 101
Study: 20385894

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Infiltration, physiotherapy, or medication
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 91
Study: 17368065

Group type: EXPERIMENTAL
Intervention: LNAA supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medical product (with or without LNAA supplements)
Number of subjects: 16
Study: 15837702

Group type: EXPERIMENTAL
Intervention: OXAFAFU high dose (hd)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: OXAFAFU low dose (ld)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: OXAFAFU (both doses)
Number of subjects: 274
Study: 11754196

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine and cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other immunosuppressives
Number of subjects: 0
Study: 9696222

Group type: EXPERIMENTAL
Intervention: Oral estrogen
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen and progestogen
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Percutaneous estrogen
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 68
Study: 8073391

Group type: EXPERIMENTAL
Intervention: Recombinant thrombomodulin analog (TME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-HIR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin sodium (HEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 0
Study: 2563788

Group type: EXPERIMENTAL
Intervention: Hepatitis-B vaccine + 7 monthly injections of HB immunoglobulin (HBIg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Hepatitis-B vaccine + 1 HBIg injection at birth
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Hepatitis-B vaccine only
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo for both vaccine and HBIg
Number of subjects: 235
Study: 31006122

Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone acetonide (20 mg in both tarsocrural joints, total 40 mg/horse)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular triamcinolone acetonide (40 mg)
Number of subjects: 10
Study: 29797689

Group type: EXPERIMENTAL
Intervention: Heat stimuli at 48-49-48 °C (traditional OA-paradigm)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electrical stimuli at 150%-180%-150% of the electrical pain perception (EPP) threshold
Number of subjects: 24

Group type: COMPARATOR
Intervention: CONTROL-STIM (30 s constant heat at 48 °C and electrical stimuli at 150% of the EPP)
Number of subjects: 24
Study: 27060379

Group type: EXPERIMENTAL
Intervention: BCG vaccine (Danish strain 1331 SSI)
Number of subjects: 4262

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 4262
Study: 24675145

Group type: COMPARATOR
Intervention: Compression stockings
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 153
Study: 22969980

Group type: EXPERIMENTAL
Intervention: PEG 4000 (20 g/day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Lactulose (15 ml/day)
Number of subjects: 216
Study: 20624256

Group type: EXPERIMENTAL
Intervention: Large breakfast consumption
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fasting (control)
Number of subjects: 32
Study: 18756471

Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (SMT)
Number of subjects: 22
Study: 16021966

Group type: EXPERIMENTAL
Intervention: Posture correction exercises in physical education classes (n=200)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group (n=213)
Number of subjects: 413
Study: 12382293

Group type: EXPERIMENTAL
Intervention: Insole with subtalar strapping (n = 42)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sock-type ankle support (n = 46)
Number of subjects: 88
Study: 9298559

Group type: COMPARATOR
Intervention: Short rest interval (40 seconds)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long rest interval (160 seconds)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both groups (short and long rest intervals)
Number of subjects: 15
Study: 1775598

Group type: EXPERIMENTAL
Intervention: Fluoxetine at 20 mg/day for at least 8 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal controls (29 individuals of similar age)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Younger depressed patients (31 individuals)
Number of subjects: 79
Study: 7340507

Group type: EXPERIMENTAL
Intervention: Systematic encouragement and community access procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard referral procedure
Number of subjects: 20
Study: 30487209

Group type: EXPERIMENTAL
Intervention: Subtherapeutic CPAP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Therapeutic CPAP
Number of subjects: 41
Study: 25349205

Group type: EXPERIMENTAL
Intervention: AST-120 (9 g/d)
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2035
Study: 25208597

Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg tadalafil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous dose of 5 mg tadalafil each morning for seven consecutive days
Number of subjects: 30
Study: 22647399

Group type: EXPERIMENTAL
Intervention: TAU plus cognitive behavioral therapy sessions, psycho-educational sessions for family members, and case management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 400
Study: 19154478

Group type: EXPERIMENTAL
Intervention: Retroperitoneal decortication with wadding using perirenal fat tissue (RDCW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple retroperitoneal decortication (SRD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (RDCW and SRD)
Number of subjects: 40
Study: 17900265

Group type: EXPERIMENTAL
Intervention: 20 mg ebastine
Number of subjects: 22
Study: 15385360

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous sufentanil (IVS)
Number of subjects: 40
Study: 11490343

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Breslow thickness, Clark level, ulceration, and patient age
Number of subjects: 961
Study: 30935461

Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 7
Study: 7649972

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study: 2375294

Group type: EXPERIMENTAL
Intervention: Overlap of lactation and pregnancy
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Short recuperative periods (less than 6 months)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Energetic stresses of overlap and short recuperative periods
Number of subjects: 504
Study: 518806

Group type: EXPERIMENTAL
Intervention: Oral preparation of dichloralphenazone and paracetamol (Paedosed)
Number of subjects: 562

Group type: COMPARATOR
Intervention: i.m. morphine and atropine
Number of subjects: 562
Study: 31644357

Group type: EXPERIMENTAL
Intervention: pTVG-HP co-administered intradermally with 200 μg GM-CSF adjuvant
Number of subjects: 99

Group type: COMPARATOR
Intervention: 200 μg GM-CSF alone
Number of subjects: 99
Study: 28235536

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group U, n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional method (group C, n=32)
Number of subjects: 64
Study: 25930144

Group type: EXPERIMENTAL
Intervention: SG1002 (400 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SG1002 (400 mg and 800 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SG1002 (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SG1002
Number of subjects: 15
Study: 23672597

Group type: EXPERIMENTAL
Intervention: Jiangtang Xiaozhi (3 capsules three times daily for 16 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22086220

Group type: EXPERIMENTAL
Intervention: Alzheimer disease (AD)
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Vascular dementia (VAD)
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Parkinson disease dementia
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Mixed dementias (AD/VAD and AD/DLB)
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Overall dementia types
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Mild diagnoses
Number of subjects: 2963
Study: 19815583

Group type: EXPERIMENTAL
Intervention: Collaborative requesting
Number of subjects: 201

Group type: COMPARATOR
Intervention: Routine requesting
Number of subjects: 201
Study: 17427065

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 98
Study: 15482360

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg/min GTN infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 32
Study: 11490238

Group type: EXPERIMENTAL
Intervention: 250 mg exisulind twice daily for 12 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9550628

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study: 9721149

Group type: EXPERIMENTAL
Intervention: Advanced distal adenoma
Number of subjects: 981

Group type: COMPARATOR
Intervention: Nonadvanced distal adenoma
Number of subjects: 981

Group type: COMPARATOR
Intervention: Not performing colonoscopy in nonadvanced distal adenoma
Number of subjects: 981
Study: 2718479

Group type: EXPERIMENTAL
Intervention: Clidinium bromide 5 mg + Magnesium citrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clidinium bromide 5 mg + Placebo liquid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo capsule + Magnesium citrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsule + Placebo liquid
Number of subjects: 40
Study: 340138

Group type: EXPERIMENTAL
Intervention: 250 mg mefenamic acid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 32.5 mg dextropropoxyphene hydrochloride plus 325 mg paracetamol
Number of subjects: 48
Study: 29474302

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus prompt laser
Number of subjects: 335

Group type: COMPARATOR
Intervention: Ranibizumab plus deferred laser
Number of subjects: 335
Study: 27861249

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60% peak oxygen uptake, 30 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) exercise (30% maximum voluntary contraction, 4×2 min bilateral)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aerobic training (8 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training (8 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 27
Study: 25452071

Group type: EXPERIMENTAL
Intervention: Early sustained reduction
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Late sustained reduction
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Temporary reduction
Number of subjects: 943

Group type: COMPARATOR
Intervention: No reduction
Number of subjects: 943
Study: 24570979

Group type: EXPERIMENTAL
Intervention: Plaster impressions
Number of subjects: 38

Group type: COMPARATOR
Intervention: Splinted vinyl polysiloxane (splinted‐VPS) impressions
Number of subjects: 38
Study: 21148048

Group type: EXPERIMENTAL
Intervention: Arterolane maleate 50 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Arterolane maleate 100 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Arterolane maleate 200 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Combination with piperaquine phosphate
Number of subjects: 229
Study: 19492313

Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPH)
Number of subjects: 43
Study: 16440537

Group type: EXPERIMENTAL
Intervention: Multifamily Asthma Group Treatment (MFAGT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Psychoeducational Asthma Intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no psychoeducational intervention)
Number of subjects: 24
Study: 15345098

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 350

Group type: COMPARATOR
Intervention: Advice and exercise
Number of subjects: 350
Study: 11759865

Group type: EXPERIMENTAL
Intervention: SRP plus minocycline microspheres
Number of subjects: 748

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 748

Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 748
Study: 9222805

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for ten days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Doxycycline plus ceftriaxone (1 g in two doses for one day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7660023

Group type: EXPERIMENTAL
Intervention: Home visits to mothers and babies at 5, 10, and 20 days after birth.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-visited control group.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Home visits to mothers and babies.
Number of subjects: 450
Study: 2894921

Group type: EXPERIMENTAL
Intervention: IV metoprolol and IV streptokinase (group 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: IV metoprolol (group 2)
Number of subjects: 25
Study: 31873098

Group type: EXPERIMENTAL
Intervention: Intermittent bright light (IBL) (9,500 lux) for 6.5 hours
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous bright light (CBL) (9,500 lux) for 6.5 hours
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous dim light (VDL) (1 lux) for 6.5 hours
Number of subjects: 21
Study: 29231617

Group type: EXPERIMENTAL
Intervention: Medication combined with acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture control group
Number of subjects: 0
Study: 25420776

Group type: EXPERIMENTAL
Intervention: Gestrinone combined with ultrasound-guided aspiration and ethanol injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ultrasound-guided aspiration and ethanol injection
Number of subjects: 68
Study: 21685354

Group type: EXPERIMENTAL
Intervention: Emergent literacy intervention consisting of eighteen 30‐min lessons delivered twice weekly to small groups of children.
Number of subjects: 640
Study: 21700817

Group type: EXPERIMENTAL
Intervention: Higher net endogenous acid production (NEAP)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Stage 4/5 CKD
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Stage 2/3 CKD
Number of subjects: 462
Study: 19332850

Group type: COMPARATOR
Intervention: Endorectal MR imaging alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Combined endorectal MR imaging and MR spectroscopic imaging
Number of subjects: 134
Study: 16542292

Group type: EXPERIMENTAL
Intervention: Alequel (autologous colonic proteins)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12740543

Group type: EXPERIMENTAL
Intervention: CaCO(3)/MFP dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: SiO(2)/MFP dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative control (brushing without dentifrice)
Number of subjects: 10
Study: 11098560

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone or new class III agents (e.g., Dofetilide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic agents
Number of subjects: 0
Study: 9328156

Group type: EXPERIMENTAL
Intervention: Clodronate (300 mg/day i.v. for 5 days followed by 1.6 g/day orally for 12 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8104200

Group type: EXPERIMENTAL
Intervention: Idazoxan (mean dose, 120 mg/day) combined with fluphenazine (mean dose, 28 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluphenazine alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 6
Study: 4042078

Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethyl loflazepate 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28984097

Group type: EXPERIMENTAL
Intervention: Intraoperative epidural infusion started preoperatively and maintained throughout
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postoperative initiation of epidural infusion after neurological examination
Number of subjects: 40
Study: 27655371

Group type: EXPERIMENTAL
Intervention: Frontal electromyographic (EMG) biofeedback associated with prophylactic pharmacological therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pharmacological treatment alone (Control Group)
Number of subjects: 27
Study: 23851514

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 160
Study: 21527896

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (phase I) followed by maintenance interventions (phase II) for 30 months
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Phase I weight loss
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern at entry, improvement in dietary pattern
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Weight regain during phase II
Number of subjects: 1032
Study: 20601737

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20084795

Group type: EXPERIMENTAL
Intervention: Mixed beam of 6‐Mev electrons (10Gy) and opposed tangential fields using 6 Mev‐photons (36 Gy) followed by 6‐Mev electrons boost to the scar of mastectomy for 4 Gy/2 fractions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-iscocentric technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isocentric technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 22
Study: 15647411

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg oral suspension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg oral suspension (hemodialysis-dependent subjects)
Number of subjects: 24
Study: 14512128

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (BANS) - 64-microg total dose (one 32-microg spray per nostril)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (BANS)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray (FPNS) - 200-microg total dose (two 50-microg sprays per nostril in study 1) and 100-microg total dose (one 50-microg spray per nostril in study 2)
Number of subjects: 371
Study: 10580711

Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) exposure (900 MHz; maximum specific absorption rate 1 W/kg) during night-time sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control night with sham exposure
Number of subjects: 0
Study: 8759957

Group type: EXPERIMENTAL
Intervention: Auditory sample discrimination task with tonal sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased sequence length
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased component duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced overlap in distributions
Number of subjects: 0
Study: 1895262

Group type: EXPERIMENTAL
Intervention: Cyclosporine (initial daily dose 5 mg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: D-penicillamine (initial daily dose 250 mg)
Number of subjects: 92
Study: 6822085

Group type: EXPERIMENTAL
Intervention: Nutritional assessment and support in ICU patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 84
Study: 31729326

Group type: EXPERIMENTAL
Intervention: Immediate blood transfusion (higher volume: 30 mL/kg whole blood / 15 mL/kg packed cells; lower volume: 20 mL/kg whole blood / 10 mL/kg packed cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate blood transfusion (20 mL/kg whole blood equivalent)
Number of subjects: 0
Study: 28323798

Group type: EXPERIMENTAL
Intervention: FiO2 80% (Supplemental perioperative oxygen therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FiO2 30% (Control group)
Number of subjects: 0